Study of FGF23s Role in Heart Damage Among Adults With Anemia and Chronic Kidney Disease

What this Trial Is About

Researchers are studying the link between anemia caused by iron deficiency and cardiovascular damage, especially in people with or without chronic kidney disease CKD. The study focuses on a protein called fibroblast growth factor 23 FGF23, which has been linked to heart problems. They aim to understand how anemia affects FGF23 levels and cardiovascular health, and to identify possible ways to prevent or reduce heart damage. The project includes several parts examining blood samples from patients with iron deficiency anemia with and without CKD studying effects in animal models including rats with anemia and CKD and testing different intravenous iron treatments to see how they affect FGF23 levels and heart health. The study also looks at how certain drugs might influence these processes and investigates the direct effects of FGF23 on heart cells in lab cultures. Participants will provide blood samples before starting iron treatment and again after 12 months. Researchers will measure various blood markers related to iron, kidney function, heart damage, and inflammation. Advanced techniques will analyze gene and protein profiles linked to the condition. The study will monitor heart health indicators and biochemical measurements over time to understand the relationship between anemia, FGF23, and cardiovascular damage.

FGF23 and Cardiovascular Damage in Anemia With an Without Chronic Kidney Disease.